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Ketorolac Use and Incidence of Postoperative Bleeding in an ERAS Colorectal
Surgical Population: A Quality Analysis of Practice
Abstract
Background Ketorolac is an effective analgesic adjunct and is currently used in Enhanced Recovery After
Surgery (ERAS) protocols. However, investigation into its safety profile is warranted in specific surgical
populations. This Quality Improvement (QI) study sought to examine the association of ketorolac to
increased postoperative bleeding risk, increased postoperative renal impairment, and 30-day readmission
within an ERAS protocol for colorectal surgery.
Methods A retrospective review was conducted of 158 patients enrolled in an existing ERAS protocol for
colorectal surgery with at least one dose of ketorolac administered in the perioperative period. Outcomes
of postoperative bleeding, 30-day readmission, and preoperative/postoperative serum creatinine levels
were assessed.
Results There was no statistically significant difference in the incidence of postoperative bleeding
compared to a known population. There was a significant association of 30-day readmissions with
documented evidence of bleeding (P = 0.037). There was no significant change in the preoperative and
postoperative serum creatinine. Multivariate logistic regression analysis found no association of
postoperative bleeding with pre-existing chronic non-steroidal anti-inflammatory drug (NSAID) use or
preoperative serum creatinine.
Conclusions Ketorolac is not associated with an increased risk of postoperative bleeding in colorectal
ERAS surgical patients. However, postoperative bleeding does predict the likelihood for 30-day
readmissions.
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Abstract
Background Ketorolac is an effective analgesic adjunct and is currently used in Enhanced
Recovery After Surgery (ERAS) protocols. However, investigation into its safety profile is
warranted in specific surgical populations. This Quality Improvement (QI) study sought to
examine the association of ketorolac to increased postoperative bleeding risk, increased
postoperative renal impairment, and 30-day readmission within an ERAS protocol for colorectal
surgery.
Methods A retrospective review was conducted of 158 patients enrolled in an existing ERAS
protocol for colorectal surgery with at least one dose of ketorolac administered in the
perioperative period. Outcomes of postoperative bleeding, 30-day readmission, and
preoperative/postoperative serum creatinine levels were assessed.
Results There was no statistically significant difference in the incidence of postoperative
bleeding compared to a known population. There was a significant association of 30-day
readmissions with documented evidence of bleeding (P = 0.037). There was no significant
change in the preoperative and postoperative serum creatinine. Multivariate logistic regression
analysis found no association of postoperative bleeding with pre-existing chronic non-steroidal
anti-inflammatory drug (NSAID) use or preoperative serum creatinine.
Conclusions Ketorolac is not associated with an increased risk of postoperative bleeding in
colorectal ERAS surgical patients. However, postoperative bleeding does predict the likelihood
for 30-day readmissions.
Keywords: Ketorolac, colorectal surgery, postoperative bleeding
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Introduction
Ketorolac, a nonselective cyclooxygenase (COX) inhibitor, is a potent analgesic frequently used
in the operating room and the inpatient setting [1, 2]. In a range of surgical populations, the use
of ketorolac has proven successful as a multimodal approach to postoperative pain management
[2, 3]. However, its use in the perioperative setting is controversial given concerns over
ketorolac’s effect on bleeding related to platelet dysfunction [4, 5]. Conflicts in reported data
have created contrariety among perioperative providers with regard to ketorolac administration
and the postoperative risks for surgical patients [4-6].
A comprehensive review of the literature concluded that in the perioperative setting,
ketorolac use does not cause an increased risk of bleeding in a multitude of surgical procedures
and patient populations [6-12]. As an effective nonopioid analgesic for mild to moderate
postoperative pain, ketorolac use warrants additional investigation to assess its safety profile in
various surgical specialties and patient populations, including colorectal surgery.
The inclusion of ketorolac in Enhanced Recovery After Surgery (ERAS) protocols
acknowledges its safety and efficacy among select surgical specialties. Ketorolac has been
proven to both provide postoperative analgesia and have an opioid-sparing effect, thus
decreasing post-surgical opioid consumption [3]. Numerous studies have evaluated the risk and
incidence of non-steroidal anti-inflammatory drug (NSAID)-induced postoperative bleeding after
surgery, but the majority of findings were inconclusive, including a meta-analysis of 27
randomized controlled trials [6]. Many providers continue to be hesitant to choose an NSAID as
a postoperative analgesic due to the uncertainty of the risk profile for bleeding. A retrospective
health record review was conducted with ERAS protocol surgical patients in the colorectal
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department of a large academic medical center to evaluate the incidence of postoperative
bleeding complications.

Material and Methods
This retrospective quality improvement project sought to determine if ketorolac use in an ERASprotocol colorectal surgical population is associated with increased postoperative bleeding,
increased rate of 30-day readmission, or a postoperative increase in serum creatinine levels. This
project was deemed exempt from the Institutional Review Board as a Quality Improvement (QI)
study. Utilizing the Lean methodology framework, a retrospective chart review was conducted in
an existing database of ERAS colorectal surgical patients at a single academic medical center
[13]. Investigators conformed to SQUIRE guidelines to ensure transparency of reporting [14].

Sample and Setting
Patient data were accessed through a database maintained by author, SS, and the electronic
medical record (EMR). Participants included in the study had undergone elective colorectal
surgeries performed between January 2015 and July 2017 and were all enrolled in an ERAS
protocol. As part of the protocol, patients received at least one dose of intravenous (IV) ketorolac
in the perioperative period, and the majority continued this therapy for up to 48 hours
postoperatively. Those who had not undergone an elective colorectal surgical procedure or had
no exposure to IV ketorolac were excluded from analysis (Figure 1).

Study Variables
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Variables collected from the EMR included age, sex, race, American Society of
Anesthesiologists (ASA) physical status, primary preoperative diagnosis, procedure type, length
of postoperative hospital stay, presence or absence of 30-day readmission, preoperative chronic
NSAID use, ketorolac dose (mg), preoperative serum creatinine level (mg/dL), day-one
postoperative serum creatinine level (mg/dL), postoperative blood transfusion, postoperative
endoscopic intervention and/or documented evidence of postoperative bleeding. The primary
study outcome, postoperative bleeding, was defined as any documented sign of bleeding during
the hospital length of stay, including the need for blood transfusion or endoscopic evaluation of
suspected bleeding. The secondary outcome of 30-day readmission was evaluated by examining
the incidence of readmission among all included patients. An additional outcome of renal
dysfunction was evaluated by comparison of preoperative and day-one postoperative serum
creatinine level. Testing for interrater reliability for data collection was negated by the use of two
researchers simultaneously reviewing records, extracting data, entering data into an electronic
database and verifying the accuracy of data entry. Discrepancies in interpretation of data were
resolved with decision rules and discussion by both researchers until agreement was reached.

Statistical Analysis
Descriptive statistics (e.g. means, standard deviations, medians and frequencies) were used to
report sample characteristics. Bivariate statistics evaluated associations between each outcome of
interest. A one-sample chi-square test was performed to evaluate bleeding risk, comparing the
study sample to a known incidence of postoperative bleeding among colorectal surgical patients
derived from a meta-analysis of colorectal surgical complication rates [15]. The WilcoxonSigned ranks test compared medians between pre- and postoperative serum creatinine levels.
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Mann-Whitney U tests compared medians for several variables between patients with and
without documented evidence of bleeding and 30-day readmissions. A multivariate logistic
regression model was constructed for bleeding and 30-day readmission to estimate the odds ratio
of the risk of bleeding. Variables were stratified to examine the influence on primary and
secondary outcomes. An α < 0.05 was set and study subjects with missing data for secondary
outcomes were not included in the calculations. The overall fit of models was evaluated using
Akaike Information Criteria (AIC) and a Hosmer-Lemeshow test for goodness of fit with p >
0.05 indicating that the fitted predicted probabilities did not deviate from the observed
probabilities of the data. Statistical analysis was performed using SPSS Version 24.0 (IBM Corp,
2016, Armonk NY) and R 3.5.1 (R Foundation, 2018, Vienna, Austria).

Results
A total of 242 patient charts were included in the ERAS database and 158 patients were selected
based upon meeting all inclusion criteria (Figure 1). The database included patients who had
multiple ERAS-protocol procedures on separate dates. If the separate entries for a single patient
met inclusion criteria, these results were included in final analyses. Participants included were
aged 18-89 years, 49.4% female, 50.6% male, with a mean age of 50.4 years (Table 1).
Demographic information for race included 73.4% white, 23.4% black and 3.2% other. Of the
underlying etiologies, 27.2% of patients had a preoperative diagnosis of cancer, 40.5% of
inflammatory bowel disease, 19.6% of diverticulitis, and 12.7% trauma or other diagnoses.
Doses of ketorolac were either 15 milligrams of IV ketorolac (20.3% of cases) or 30 milligrams
of IV ketorolac (79.7% of cases). A total of 8.8% of patients had a hospital readmission for allcauses within 30 days of discharge (Table 2). Of the patients who had a 30-day readmission, 4
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(28.6%) had evidence of bleeding upon readmission or at some time during the primary
hospitalization. Twelve patients (7.6%) had documented evidence of postoperative bleeding
(Table 2). When compared to a known incidence of postoperative bleeding in colorectal surgical
patients (7.6%), a Pearson chi-square analysis indicated no statistically significant difference
between our sample data and a known comparator [𝝌2(1, n=158) < 0.001, p = 0.999] [14].
Examining the primary and secondary outcomes of interest as they relate to sample
characteristics, there was a significant influence on postoperative bleeding risk from those who
had a diagnosis of diverticulitis (p = 0.005) (Table 2). A significant difference (p = 0.013)
existed between the proportion of patients who had evidence of bleeding and had subsequent
readmission versus those who had no signs of postoperative bleeding. As it relates to 30-day
readmission, a Fisher’s exact test of proportions indicated a significant difference in the
proportion of patients requiring a transfusion (p = 0.004) or endoscopic intervention (p = 0.007)
who also had evidence of postoperative bleeding and were readmitted within 30-days versus
those with no evidence of postoperative bleeding (Table 2). Bivariate statistics utilizing a MannWhitney U test showed a significant difference in the median length of stay between the patients
who had signs of bleeding and those who did not (4 days vs. 3 days, respectively, p = 0.008)
(Table 2). There was no significant influence of gender, race, ASA status, type of procedure, or
chronic NSAID use on the primary and secondary outcomes of interest (Tables 2, 3, 4).

Risk of Bleeding
Compared to those with preoperative diagnosis of diverticulitis, individuals with cancer were
93% less likely to have postoperative bleeding [Adjusted Odds Ratio (AOR) = 0.068; 95% CI =
0.003, 0.484; p = 0.022] (Table 3).
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Odds of 30-Day Readmission
A multivariate approach identified that individuals who were readmitted within 30 days had a 6
times greater odds of having had evidence of postoperative bleeding compared to those patients
who were not readmitted (AOR = 6.163; 95% CI = 1.150, 32.186; p = 0.028) (Table 3). Further,
patients who had evidence of postoperative bleeding had a 5 times greater risk of 30-day
readmission (AOR = 5.436; 95% CI = 1.221, 21.646; p = 0.018) (Table 4). The influence of
preoperative chronic NSAID use and hospital length of stay were insignificant related to 30-day
readmission (Table 4).

Serum Creatinine Levels
There was no statistically significant change in postoperative creatinine levels for patients who
received any dose of intraoperative IV ketorolac (z = -7.1, p = 0.667).

Discussion
Bleeding
This study is among few to evaluate the incidence of postoperative bleeding in a sample of
colorectal surgical patients receiving ketorolac as part of an ERAS protocol. Findings from this
retrospective review found no difference in our sample’s bleeding complication rate when
compared to a population of colorectal surgical patients [15]. This suggests that there may be no
increased risk of bleeding associated with ketorolac use in the colorectal surgical population.
Other studies have also corroborated that perioperative administration of ketorolac poses no
increased risk for bleeding with many types of surgeries [6-12]. Notably, a 2011 meta-analysis of
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27 randomized controlled trials found no significant increase in postoperative bleeding in
patients who received ketorolac when compared to control groups [6].
Having a complication of bleeding did contribute to a statistically significant longer
median for length of postoperative hospital stay, 4 days for patients with postoperative bleeding,
and 3 days for patients without. Shorter length of hospital stay is associated with lower costs
when compared to patients with longer stay, and earlier discharge has been linked with lower 30day readmission rates [16, 17]. Overall, surgical complications increase length of hospital stay
[18], and studies have shown significantly shorter length of stay between ERAS and non ERAS
patients by 2.6 days [19]. Our data suggests that within this sample of ERAS-protocol colorectal
surgical patients, postoperative bleeding increases length of hospitalization by 1 day.
Compared to those with cancer diagnoses, individuals with diverticulitis as an indication
for colorectal surgery have a 15 times greater odds of postoperative bleeding. This finding is in
contrast with current data suggesting no difference between major complication rates based on
surgical indication [19, 20]. One study found malignant neoplasm to be the surgical indication
associated with higher complication rates [21]. However, both aspirin and NSAID use has been
linked to increased lower gastrointestinal bleeding in patients with diverticular disease [22, 23].
Because our sample contained a small proportion of patients with diverticulitis, our finding must
be cautiously interpreted but underscores the need to further investigate the association between
diverticular disease and postoperative bleeding.
There was no association between preoperative chronic NSAID use and postoperative
bleeding. However, a 2011 meta-analysis linked chronic aspirin and NSAID therapies with
increased risk of lower gastrointestinal bleeding in non-surgical patients with diverticulitis [23].
Our sample - in which 100% of patients received perioperative ketorolac - showed no deviation
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of postoperative bleeding risk from the known comparator, in addition to no increased risk with
chronic aspirin or NSAID therapy [15].

30-Day Readmission
This study demonstrated that patients with evidence of postoperative bleeding were 7 times more
likely to be readmitted within 30 days of postoperative discharge. If patients received a blood
transfusion, this risk was 11 times greater. Readmission rates within 30 days of discharge are
important metrics for hospitals and healthcare providers due to reduced financial reimbursement
for the subsequent hospitalization. This reduction in payment to hospitals from the Centers for
Medicare & Medicaid Services (CMS) for potentially preventable hospitalizations is estimated to
reduce spending by approximately $500 million in 2019 [24]. In addition, this regulation in
reimbursement holds hospitals accountable to reduce re-hospitalization. Our results add to the
evidence showing that higher complication rates are associated with increased readmissions,
regardless of ERAS or non-ERAS protocol [18, 19].

Serum Creatinine
Aside from bleeding risk, a concern when using NSAIDs in the perioperative setting is the risk
of renal impairment. The analysis showed no statistically significant change in postoperative
creatinine levels for patients who received any dose of intraoperative IV ketorolac. This finding
is supported by a 2007 Cochrane review that included 23 trials and concluded that NSAID
administration reduces creatinine clearance by 16 mL/min on postoperative day 1 and causes no
change in serum creatinine levels compared to placebo administration in patients with normal
renal function [25]. This decrease in creatinine clearance was deemed as clinically insignificant
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and does not risk renal failure. Similarly, our findings apply to patients with normal baseline
renal function, as patients with preoperative renal disease were excluded from the full ERAS
protocol and did not receive ketorolac. Perioperative ketorolac has an acceptable safety profile
when administered to those with normal renal function.

Limitations
While our study included all eligible patients enrolled in an ERAS protocol, the sample size was
relatively small. This may have affected inferences drawn from the results and contributed to
wide confidence intervals around mean values. Limited sample sizes may be less representative
of broader samples and hamper the ability to generalize findings to a larger population. However,
data generated from this exploratory project support the need for future prospective
investigations of ketorolac with colorectal surgical populations.
With any observational study, there is always potential for bias in the results due to
unobserved or unaccounted-for mediator/moderator of the outcome of interest. To reduce this
bias, our sample was all-inclusive of eligible patients, and data were collected using two
researchers who simultaneously extracted and verified all data. The sample for this project was
relatively homogenous with each patient receiving standard care directed by an ERAS protocol.
This reduced practice variations in the management of patients that may have introduced
potential confounding variables influencing outcomes with ketorolac. The lack of a control group
is also a limitation that would have allowed a comparison of bleeding complications in those
having colorectal surgery but not receiving ketorolac.

Conclusion
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In conclusion, ketorolac is not associated with an increased risk of postoperative bleeding in
colorectal ERAS surgical patients. Ketorolac is further not associated with a decrease in
postoperative renal function as evidenced by a change in serum creatinine levels. An association
does exist between postoperative bleeding and increased 30-day readmission rates, as well as
increased length of stay.
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Table 1: Sample Characteristics (n = 158)

Age (years)
Pre Creatinine (mg/dL)
POD 1 Creatinine (mg/dL)
Length of Stay (days)

Mean (SD)
50.4 (16.9)
0.85 (0.2)
0.87 (0.2)
3.3 (1.8)

N
%
Gender
Female
78 49.4%
Male
80 50.6%
Race
Black
37 23.4%
White
116 73.4%
Other
5
3.2%
ASA Classification
1
3
1.9%
2
104 65.8%
3
51 32.3%
Diagnosis
Cancer
43 27.2%
IBD
64 40.5%
Diverticulitis
31 19.6%
Trauma/Other
20 12.7%
Procedure
Laparoscopic colectomy
99 62.7%
Exploratory laparotomy
23 14.6%
Closure enterostomy
22 13.9%
Other
14
8.9%
Ketorolac Dose
30 mg
126 79.7%
15 mg
32 20.3%
30-day Readmission
No
144 91.1%
Yes
14
8.9%
Transfusion
No
149 94.3%
Yes
9
5.7%
Endoscopic Intervention
No
156 98.7%
Yes
2
1.3%
Evidence of Bleeding
No
146 92.4%
Yes
12
7.6%
Preoperative NSAID use
No
122 77.2%
Yes
36 22.8%
POD 1 = post-operative day 1; ASA = American Society of Anesthesiologists; IBD = inflammatory bowel disease
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Table 2: Comparison of Outcomes Based on Sample Characteristics*
Evidence of Postoperative Bleeding
30-day Readmission
No
Yes
No
Yes
Median
Median
P-value
Median
Median
P-value
Age
50.50
59.50
0.217
50.51
52.50
0.801
Pre Creatinine
0.84
0.77
0.070
0.84
0.90
0.476
POD 1 Creatinine
0.84
0.79
0.293
0.83
0.89
0.383
Ketorolac Dose
30
30
0.242
30
40
0.912
Length of Stay
3.0
4.0
0.008
3
3.5
0.138
N
N
P
N
N
P
Gender
0.999
0.160
Female
72
6
74
4
Male
74
6
70
10
Race
0.528
0.411
Black
36
1
35
2
White
105
11
105
11
Other
5
4
1
ASA
0.198
0.355
1
3
0
3
0
2
93
11
92
12
3
50
1
49
2
Diagnosis
0.005
0.779
Cancer
42
1
40
3
IBD
62
2
59
5
Diverticulitis
24
7
27
4
Trauma/Other
18
2
18
2
Procedure
0.641
0.404
Laparoscopic colectomy
92
7
92
7
Exploratory laparotomy
22
1
21
2
Closure enterostomy
20
2
18
4
Other
12
2
13
1
Readmission
0.013
No
136
8
Yes
10
4
Transfusion
0.000
0.004
No
142
7
139
10
Yes
4
5
5
4
Endoscopic
0.147
0.007
No
145
11
144
12
Yes
1
1
0
2
NSAID
0.3
0.738
No
111
11
110
12
Yes
35
1
34
2
* Measures of association between continuous variables and the dichotomous outcomes assessed using Mann
Whitney U test and Fisher’s Exact for categorical variables.
POD 1 = post-operative day 1; ASA = American Society of Anesthesiologists; IBD = inflammatory bowel disease;
NSAID = non-steroidal anti-inflammatory drug
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Table 3: Primary Outcome: Odds of Bleeding
t
AIC= 80.9
OR
LCI
UCI
P
Intercept
0.036
0.002
0.519
0.021
Age
1.038
0.986
1.096
0.162
Preop NSAID Use
0.272
0.013
1.857
0.258
30-day Readmission
6.163
1.150
32.186
0.028
Diagnosis
Cancer
0.068
0.003
0.484
0.022
Trauma/Other
0.419
0.052
2.295
0.348
Diverticulitis
Ref
IBD
0.173
0.022
0.915
0.054
Gender
Female
Ref
Male
0.890
0.192
4.005
0.878
t
= Akaike information criterion (AIC)
OR = Odds ratio; LCI = Lower confidence interval; UCI = upper confidence interval
IBD = inflammatory bowel disease; NSAID = non-steroidal anti-inflammatory drug
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Table 4: Secondary Outcome: Odds of Readmission
t
AIC= 94.4
OR
LCI
UCI
Intercept
0.046
0.013
0.141
Postop Bleeding
5.436
1.221
21.646
Preop NSAID Use
0.576
0.083
2.425
Length of Stay
1.186
0.889
1.517
t

P
0.000
0.018
0.500
0.193

= Akaike information criterion (AIC)
OR = Odds ratio; LCI = Lower confidence interval; UCI = upper confidence interval
NSAID = non-steroidal anti-inflammatory drug
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Total ERAS database
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Records screened
(n = 242)
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No postoperative bleeding
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Evidence of postoperative
bleeding
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Figure 1

Flow Diagram: Patient Selection Process for Quality Improvement.

